» Articles » PMID: 25849412

The Role of Polymerase Chain Reaction of High-risk Human Papilloma Virus in the Screening of High-grade Squamous Intraepithelial Lesions in the Anal Mucosa of Human Immunodeficiency Virus-positive Males Having Sex with Males

Abstract

Objectives: To evaluate the advantages of cytology and PCR of high-risk human papilloma virus (PCR HR-HPV) infection in biopsy-derived diagnosis of high-grade squamous intraepithelial lesions (HSIL = AIN2/AIN3) in HIV-positive men having sex with men (MSM).

Methods: This is a single-centered study conducted between May 2010 and May 2014 in patients (n = 201, mean age 37 years) recruited from our outpatient clinic. Samples of anal canal mucosa were taken into liquid medium for PCR HPV analysis and for cytology. Anoscopy was performed for histology evaluation.

Results: Anoscopy showed 33.8% were normal, 47.8% low-grade squamous intraepithelial lesions (LSIL), and 18.4% HSIL; 80.2% had HR-HPV. PCR of HR-HPV had greater sensitivity than did cytology (88.8% vs. 75.7%) in HSIL screening, with similar positive (PPV) and negative predictive value (NPV) of 20.3 vs. 22.9 and 89.7 vs. 88.1, respectively. Combining both tests increased the sensitivity and NPV of HSIL diagnosis to 100%. Correlation of cytology vs. histology was, generally, very low and PCR of HR-HPV vs. histology was non-existent (<0.2) or low (<0.4). Area under the receiver operating characteristics (AUROC) curve analysis of cytology and PCR HR-HPV for the diagnosis of HSIL was poor (<0.6). Multivariate regression analysis showed protective factors against HSIL were: viral suppression (OR: 0.312; 95%CI: 0.099-0.984), and/or syphilis infection (OR: 0.193; 95%CI: 0.045-0.827). HSIL risk was associated with HPV-68 genotype (OR: 20.1; 95%CI: 2.04-197.82).

Conclusions: When cytology and PCR HR-HPV findings are normal, the diagnosis of pre-malignant HSIL can be reliably ruled-out in HIV suppression with treatment protects against the appearance of HSIL [corrected].

Citing Articles

Safety and Immunogenicity of the Nonavalent Human Papillomavirus Vaccine in Women Living with HIV.

Hidalgo-Tenorio C, Moya R, Omar M, Munoz L, Sampedro A, Lopez-Hidalgo J Vaccines (Basel). 2024; 12(8).

PMID: 39203964 PMC: 11359547. DOI: 10.3390/vaccines12080838.


Epidemiological distribution of high-risk human papillomavirus genotypes and associated factors among patients with esophageal carcinoma at Bugando medical center in Mwanza, Tanzania.

Ndemela L, Ottoman O, Chitemo H, Minja C, Rambau P, Kidenya B BMC Cancer. 2024; 24(1):932.

PMID: 39090618 PMC: 11293061. DOI: 10.1186/s12885-024-12657-0.


Role of Low-Risk HPV PCR Monoinfection in Screening for HSIL and Anal Cancer in Men Who Have Sex with Men Living with HIV.

Garcia-Martinez C, Calle-Gomez I, Lopez-Hidalgo J, Gomez-Ronquillo P, Omar-Mohamed Balgahata M, Hidalgo-Tenorio C Int J Mol Sci. 2023; 24(6).

PMID: 36982714 PMC: 10056681. DOI: 10.3390/ijms24065642.


Sexually Transmitted Infections Treatment Guidelines, 2021.

Workowski K, Bachmann L, Chan P, Johnston C, Muzny C, Park I MMWR Recomm Rep. 2021; 70(4):1-187.

PMID: 34292926 PMC: 8344968. DOI: 10.15585/mmwr.rr7004a1.


Negative Predictive Value of Human Papillomavirus Testing: Implications for Anal Cancer Screening in People Living with HIV/AIDS.

Wang Y, Wang Y, Gaisa M, Sigel K, Zheng W, Liu Y J Oncol. 2020; 2020:6352315.

PMID: 32411239 PMC: 7204264. DOI: 10.1155/2020/6352315.


References
1.
Salit I, Lytwyn A, Raboud J, Sano M, Chong S, Diong C . The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS. 2010; 24(9):1307-13. DOI: 10.1097/QAD.0b013e328339e592. View

2.
Diamond C, Taylor T, Aboumrad T, Bringman D, Anton-Culver H . Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis. 2005; 32(5):314-20. DOI: 10.1097/01.olq.0000162366.60245.02. View

3.
Martin Andres A, Femia Marzo P . Chance-corrected measures of reliability and validity in K x K tables. Stat Methods Med Res. 2005; 14(5):473-92. DOI: 10.1191/0962280205sm412oa. View

4.
Weis S . Current treatment options for management of anal intraepithelial neoplasia. Onco Targets Ther. 2013; 6:651-65. PMC: 3684220. DOI: 10.2147/OTT.S38217. View

5.
Chin-Hong P, Palefsky J . Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002; 35(9):1127-34. DOI: 10.1086/344057. View